Advertisement
Research Article

Both Baseline Clinical Factors and Genetic Polymorphisms Influence the Development of Severe Functional Status in Ankylosing Spondylitis

  • Ruxandra Schiotis mail,

    Elena.Schiotis@umfcluj.ro

    Affiliations: Department of Pharmacology, “Iuliu Hatieganu” University of Medicine and Pharmacy and SCBI- Rheumatology Department, Cluj-Napoca, Romania, Department of Rheumatology, University Hospital “Reina Sofía”/IMIBIC, Córdoba, Spain

    X
  • Nerea Bartolomé,

    Affiliation: Department of R+D, Progenika Biopharma SA, Derio-Vizcaya, Spain

    X
  • Alejandra Sánchez,

    Affiliation: Department of Rheumatology, “Puerta de Hierro Majadahonda”, University Hospital, Madrid, Spain

    X
  • Magdalena Szczypiorska,

    Affiliation: Department of R+D, Progenika Biopharma SA, Derio-Vizcaya, Spain

    X
  • Jesús Sanz,

    Affiliation: Department of Rheumatology, “Puerta de Hierro Majadahonda”, University Hospital, Madrid, Spain

    X
  • Eduardo Cuende,

    Affiliation: Department of Rheumatology, University Hospital “Príncipe de Asturias”, Alcalá de Henares, Madrid, Spain

    X
  • Eduardo Collantes Estevez,

    Affiliation: Department of Rheumatology, University Hospital “Reina Sofía”/IMIBIC, Córdoba, Spain

    X
  • Antonio Martínez,

    Affiliation: Department of R+D, Progenika Biopharma SA, Derio-Vizcaya, Spain

    X
  • Diego Tejedor,

    Affiliation: Department of R+D, Progenika Biopharma SA, Derio-Vizcaya, Spain

    X
  • Marta Artieda,

    Affiliation: Department of R+D, Progenika Biopharma SA, Derio-Vizcaya, Spain

    X
  • Anca Buzoianu,

    Affiliation: Department of Pharmacology, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania

    X
  • Juan Mulero

    Affiliation: Department of Rheumatology, “Puerta de Hierro Majadahonda”, University Hospital, Madrid, Spain

    X
  • Published: September 12, 2012
  • DOI: 10.1371/journal.pone.0043428

About the Authors

Ruxandra Schiotis
Department of Pharmacology, “Iuliu Hatieganu” University of Medicine and Pharmacy and SCBI- Rheumatology Department, Cluj-Napoca, Romania
Ruxandra Schiotis, Eduardo Collantes Estevez
Department of Rheumatology, University Hospital “Reina Sofía”/IMIBIC, Córdoba, Spain
Nerea Bartolomé, Magdalena Szczypiorska, Antonio Martínez, Diego Tejedor, Marta Artieda
Department of R+D, Progenika Biopharma SA, Derio-Vizcaya, Spain
Alejandra Sánchez, Jesús Sanz, Juan Mulero
Department of Rheumatology, “Puerta de Hierro Majadahonda”, University Hospital, Madrid, Spain
Eduardo Cuende
Department of Rheumatology, University Hospital “Príncipe de Asturias”, Alcalá de Henares, Madrid, Spain
Anca Buzoianu
Department of Pharmacology, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania

Corresponding Author

Email: Elena.Schiotis@umfcluj.ro

Competing Interests

The authors declare the following interests: M.S., N.B., M.A., A.M. and D.T. are currently employees of Progenika Biopharma, SA. A.S. is supported by an unrestricted grant from Pfizer. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials. All other authors have declared no conflicts of interest.

Author Contributions

Conceived and designed the experiments: RS AS JS ECE AB JM. Performed the experiments: NB MS AM DT MA. Analyzed the data: RS NB AS MS DT MA ECE JM. Contributed reagents/materials/analysis tools: AS ECE JM JS EC AB. Wrote the paper: RS AS NB ECE JM.